ClearPoint Neuro, Inc. (CLPT) is a commercial-stage medical device company developing minimally invasive neurosurgical platforms and biologics and drug-delivery systems for the brain. Its analyst coverage is unusually thin, which is itself a meaningful part of the story. Three recent, attributable targets form the basis of the central target: Lake Street's Frank Takkinen holds a Buy with a $25 target, lowered from $30; Stifel's Tom Stephan holds a Buy with a $22 target, lowered from $25; and B. Riley's Anderson Schock holds a Buy with a $30 target, raised from $20 in June 2026.
The arithmetic mean of $22, $25 and $30 is $25.67, which rounds to a central target of $26. Some data providers count only two active targets and show an average near $23.50, reflecting how small and shifting this coverage set is. The roughly $22-to-$30 spread is wide, and the views diverge mainly on how quickly management's heavy investment in its highest-return opportunities converts into growth. Bullish analysts emphasize a broad base of more than 60 active biopharma partners, while more cautious revisions reflect concern that elevated spending will pressure near-term results.
The stock trades near $9.11, not far above its 52-week low and well below a 52-week high near $29.60. That puts the $26 target roughly 185% above the recent price — a very large move that would require the shares to reclaim most of the ground lost over the past year. For context, ClearPoint Neuro reported revenue of about $12.1 million and a GAAP net loss of roughly $9.6 million for the quarter ended March 31, 2026, versus revenue of about $8.5 million and a loss of roughly $6.0 million a year earlier, underscoring a growth-plus-investment profile rather than a profitable, self-funding one. Any path toward the target would likely depend on sustained revenue expansion, progress in partner programs, and a demonstration that elevated spending is producing returns.
The clearest support is the partnership model. ClearPoint Neuro's platform sits at the center of cell and gene therapy and drug delivery into the brain, an area where biopharma collaborators need enabling technology regardless of which individual drug succeeds. Analysts have pointed to the diversified customer base and to "de-risked" expectations after management reset its near-term growth bar to focus on the best return-on-investment opportunities. Positive partner milestones, new collaborations, and a clean quarterly print could all act as catalysts, and a re-acceleration of revenue growth would be the most direct fundamental support for a higher CLPT valuation.
The principal obstacle is the company's deliberate investment cycle, which Lake Street noted will pressure near-term growth and could weigh on shares. Regulatory risk is also live: analysts cited FDA feedback on a partner program as a factor in lowering their fair-value estimates, and a September clinical setback at partner uniQure reminded investors how dependent sentiment can be on outcomes outside ClearPoint Neuro's control. Insider selling has also been reported over recent quarters. With no earnings yet, the stock's valuation rests heavily on future execution, and any slippage in partner programs or slower-than-expected revenue conversion could keep the shares anchored well below $26.
Technically, the shares are in a structurally weak position, trading near the bottom of a 52-week range that spans roughly $8 to $29. The area around the 52-week low near $8 represents a key support zone, while any recovery would first need to clear intermediate levels before testing the prior high near $29.60 — a level just above the $26 target. The wide gap between the current price and the analyst targets reflects how far the stock has fallen and how much would need to go right for the shares to re-rate.
Analyst price targets generally reflect a research horizon of about 12 months, though the firms covering ClearPoint Neuro do not all disclose identical timeframes, so the $26 figure should be read as a directional estimate rather than a dated prediction. The most immediate catalyst is the company's third-quarter 2026 earnings report, scheduled for October 28, 2026. Investors should watch revenue growth, spending and margin trajectory, guidance, any update on the FDA feedback affecting partner programs, new or expanded biopharma collaborations, and analyst target revisions following the report.
For traders looking to track stocks like CLPT more efficiently, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell or Hold signals from changing market conditions, technical behavior and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions and spot shifting trends without manually scanning the market. Explore AI Daily Buy/Sell Signals to see how AI-driven signals can support a more disciplined workflow.
Can ClearPoint Neuro reach $26? The question is answerable only in terms of what would have to happen. The $26 central target is the rounded average of three Buy-rated analyst targets spanning $22 to $30, and it implies a roughly 185% move from a stock trading near its 52-week low. That is a very large gap, supported in theory by a differentiated partnership model and reset expectations, but heavily constrained by an ongoing investment cycle, regulatory and partner-dependent risk, and thin coverage. The upcoming quarterly report and any partner-program or FDA updates are the next concrete signals on whether the fundamentals can begin closing that gap.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | +7.19% | ||
| ICUI - CLPT | 57% Loosely correlated | -1.66% | ||
| ISRG - CLPT | 46% Loosely correlated | -1.27% | ||
| A - CLPT | 45% Loosely correlated | +0.87% | ||
| NVST - CLPT | 45% Loosely correlated | -0.34% | ||
| SMTI - CLPT | 43% Loosely correlated | -0.55% | ||
More | ||||
| Ticker / NAME | Correlation To CLPT | 1D Price Change % |
|---|---|---|
| CLPT | 100% | +7.19% |
| Health Services category (240 stocks) | 4% Poorly correlated | +2.17% |
| Medical/Nursing Services category (139 stocks) | 3% Poorly correlated | +2.12% |